Archways Recovery Centers
If You Are Dependent on Kratom, You Are Dependent on an Opioid. That Changes What Treatment Should Look Like
People stopping kratom are routinely told it is just a plant and that what they are experiencing cannot be withdrawal. The clinical literature says otherwise, and it also says what tends to work.
9 min read · Updated July 2026
General health information | Not a diagnosis, treatment recommendation, or dosing guidance | Mesa, Arizona
The Sentence That Keeps People Out of Treatment
It arrives in some form from almost everyone. A partner, a friend, occasionally a clinician. It is a plant. You buy it at the gas station. It is not like you are on heroin.
The person hearing it has usually tried to stop three or four times, has experienced something that felt exactly like the flu crossed with panic, and has concluded that if this were real withdrawal somebody would have taken it seriously by now. So they carry on, and the dose creeps, and years pass.
The pharmacology is not ambiguous. Kratom’s principal alkaloids act as partial agonists at the mu-opioid receptor, with additional activity at kappa and delta receptors. Stopping after sustained use produces a withdrawal syndrome consistent with opioid withdrawal, and clinicians have documented it using the same instrument they use for any other opioid, the Clinical Opiate Withdrawal Scale.
That is the whole point of this page. Not to alarm anyone about a substance many people use without difficulty, but to make clear that if dependence has developed, it is a recognizable clinical problem with a recognizable clinical response.
“I Take Kratom” No Longer Describes One Thing
This is the part that has changed most, and it is why old advice about kratom has quietly stopped applying.
Kratom leaf contains over fifty alkaloids. The dominant one is mitragynine. A second, 7-hydroxymitragynine or 7-OH, occurs only as a minor constituent, comprising less than two percent of the total alkaloid content of natural leaf. But 7-OH is substantially more potent at the mu-opioid receptor than mitragynine, and more potent than classical opioids including morphine.
Because there is too little 7-OH in the leaf to extract economically, manufacturers instead purify mitragynine in bulk and chemically convert it. The result is semi-synthetic: a natural starting compound, partially synthesized into the more potent version. Those concentrated products are then sold as tablets, gummies, shots and lozenges, in the same shops, under the same word.
Why this matters clinically rather than just legally. Leaf preparations tend to act more stimulant-like at low doses, with opioid-like effects emerging at higher ones. Concentrated 7-OH behaves like a strong opioid from the start. Two people can both say they use kratom daily and be describing substantially different pharmacological situations, with different dependence trajectories and different withdrawal.
In July 2025 the FDA formally recommended that the DEA place concentrated 7-OH in Schedule I, explicitly targeting these concentrated and semi-synthetic products rather than natural leaf. State positions have been moving since, in different directions and at different speeds. Kratom itself remains legal to buy in Arizona, which means the products are on open shelves and the person using them has had no reason to think of it as a drug problem.
The Loop That Brings Most People Here
A large proportion of people who use kratom report using it specifically to reduce or replace prescription or illicit opioid use. That is not a fringe pattern, it is one of the main reasons the substance took hold in the United States, and it usually starts as a genuinely reasonable attempt at self-rescue.
The clinical literature contains this sequence repeatedly. One published case describes a man who came off prescription opioids, used kratom for a year to manage withdrawal and chronic pain, and developed tolerance and withdrawal to the kratom, with worsening depression, anxiety and pain along the way. Another describes a woman who had been abstinent from opioids for six months while taking a daily 7-OH extract, and presented to an emergency department in withdrawal.
Nobody in either story did anything stupid. They substituted one mu-opioid agonist for another, less regulated one, and the receptors did not know the difference.
What the Evidence Says About Treating It
This is where the practical value sits, and it is worth stating the limitation first. There are no formal treatment guidelines for opioid use disorder arising from kratom use. What exists is a growing body of case series, and they point consistently in one direction.
| What clinicians have reported | Why it matters to somebody stopping |
|---|---|
| Buprenorphine and buprenorphine-naloxone have been used successfully for kratom withdrawal and dependence across multiple case series | The condition is treatable with established opioid use disorder medication rather than willpower and a bad two weeks |
| Required dose appears to correlate with the amount of kratom previously used | Accurate reporting of your actual use directly affects whether treatment is adequate |
| A veteran-population series reported induction as early as eight hours after last use, with maintenance dosing similar to that used in opioid use disorder | Timing differs from traditional opioids, which is exactly the kind of detail an unfamiliar prescriber may not know |
| Prolonged withdrawal symptoms were reported despite treatment in some cases | A longer tail than expected is documented, not a sign that something is wrong with you |
| Polysubstance use alongside kratom may require a higher level of care | Honest disclosure of everything else in the picture changes the plan for the better |
One case series of twenty-eight patients who named kratom as their primary substance found duration of use ranging from one month to twenty-five years. That range is worth sitting with. This is not a young person’s novelty problem.
An important boundary. Everything above describes what has been reported in the literature. It is not dosing guidance and it is not a recommendation for any individual. Buprenorphine induction is a medical decision made by a prescriber who has assessed you, and getting the timing wrong can precipitate severe withdrawal. Nothing on this page should be used to plan your own taper or induction.
The Part About Mood That Gets Missed
Something notable recurs in these cases. Depression and anxiety appear repeatedly, and in at least one published case both resolved several months after appropriate treatment began, to the point that the patient discontinued antidepressant and anxiolytic medication.
The direction of causation is genuinely hard to untangle in any individual, which is the honest position. Sustained opioid receptor activity affects mood regulation. Chronic dependence on a substance you have been told is not a real problem produces its own demoralization. Many people started using kratom for pain or low mood in the first place.
What follows practically is that treating the kratom use and the mood symptoms as one integrated problem is more likely to work than treating either alone, which is the standard argument for co-occurring care and the reason it is built into the program here rather than referred out. That is covered on the dual diagnosis page.
What to Actually Tell a Clinician
Because product categories vary so widely, the single most useful thing you can do is describe your use precisely. Patients routinely arrive at assessment unsure what they have been taking, and that uncertainty makes the clinical picture harder to read.
Bring this information, and bring the packaging if you have it
The format. Leaf powder, capsules, liquid extract, tablets, gummies, shots. These are not grades of one product.
Whether the label mentions 7-OH. If it does, say so first. It changes the assessment.
How much, honestly. Grams per day for leaf, or milligrams and number of servings for concentrates. Rounding down is the most common and least helpful instinct here.
How often. Concentrated products often have a shorter duration than leaf, which drives more frequent dosing, and dosing frequency tells a clinician a great deal.
How long. Months or years, and whether the dose has escalated.
What else is in the picture. Alcohol, prescribed medication, anything else. Polysubstance patterns change the level of care that is appropriate.
Where Structured Outpatient Care Fits
Medication for withdrawal, where it is indicated, is one component and it is prescribed by a medical provider. It is not the whole of treatment, and the case literature reflects that: patients are described moving from medically managed withdrawal into structured treatment rather than being discharged once the acute phase passes.
That second stage is what an intensive outpatient program provides. Twelve hours of clinical group work a week plus individual therapy, addressing the reasons the substance was doing a job in the first place, whether that was pain, anxiety, insomnia, trauma or an earlier opioid problem that was never resolved. The escalation pattern that is so common with these products is a feature of the pharmacology and the product landscape, not a character defect, and treatment that treats it as a character defect will not hold.
How the week is structured is set out on the intensive outpatient page. Where the living situation is working against recovery, structured sober living is available alongside it.
Questions People Ask
Is kratom addictive, or is that overstated?
Many people use it without developing dependence, and that is true of most substances. Sustained use can produce tolerance and a withdrawal syndrome, and kratom use disorder appears in the clinical literature with a growing case base. Both things are true at once, and the question that matters is not what happens to people in general but what has been happening to you.
Can I just taper down on my own?
Some people do. Self-taper is reported to be considerably harder with concentrated products than with leaf, because of deeper receptor adaptation and faster-onset withdrawal. If you have tried more than once and it has not held, that is information about the substance rather than about your resolve, and it is a reason to get an assessment rather than to try harder alone.
Will a urine drug screen detect kratom?
Standard opioid panels generally do not detect kratom alkaloids, which is one reason use goes unrecognized. Specific testing exists and has been used in treatment settings. Tell your clinician about your use rather than assuming a screen will surface it.
How long does withdrawal last?
Acute symptoms in reported cases resemble opioid withdrawal in shape and timing, but prolonged symptoms have been documented despite treatment. Anyone promising you a fixed number of days is guessing, and the honest answer is that it varies with product, dose and duration of use.
I only use it for pain. Is that different?
The reason for use does not change the receptor pharmacology, though it does change the treatment plan, because the pain still needs addressing once the kratom stops. That is a conversation for assessment, and it is a better conversation than the one that happens after an unplanned stop.
Is it legal where I live?
Kratom remains legal to buy in Arizona, while a small number of states ban it and the federal position on concentrated 7-OH is actively moving following the FDA’s 2025 scheduling recommendation. Legality varies and is changing, so check the current position for your state rather than relying on any article, including this one.
The triumphant arch through which you pass to freedom.
Archways Recovery Centers provides intensive outpatient addiction treatment for adult men and women in Mesa, Arizona, serving Gilbert, Chandler, Tempe, Scottsdale, Phoenix and the wider East Valley. An overdose is a medical emergency and warrants a 911 call without delay.
References
Treatment of kratom withdrawal and dependence with buprenorphine/naloxone: a case series and systematic literature review. Journal of Addiction Medicine, on withdrawal consistent with opioid withdrawal, COWS scoring, and the absence of formal treatment guidelines.
Broyan VR, Brar JK, Allgaier T, Allgaier JT. Long-term buprenorphine treatment for kratom use disorder: a case series, 2022, including twenty-eight patients and duration of use from one month to twenty-five years.
Lei J, Butz A, Valentino N. Management of kratom dependence with buprenorphine/naloxone in a veteran population, 2021, on induction timing, maintenance dosing, prolonged withdrawal and polysubstance considerations.
A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: effects of buprenorphine in clinical management. PubMed.
The successful use of buprenorphine to manage kratom withdrawal secondary to self-treatment of opioid withdrawal, 2025, concerning a 7-hydroxymitragynine extract.
US Food and Drug Administration, FDA and Kratom, on 7-OH as a minor constituent of natural leaf with substantially greater mu-opioid receptor potency than mitragynine and morphine, and the July 2025 scheduling recommendation for concentrated 7-OH.
From kratom to 7-hydroxymitragynine: evolution of a natural remedy into a public-health threat, on measured 7-OH concentrations in leaf and post-harvest chemistry.